Media

Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)

Vicore Pharma has successfully carried out a directed share issue of approximately SEK 100 million

Vicore Pharma raises approximately SEK 782 million through an oversubscribed rights issue

BONESUPPORT – Additional data from SOLARIO study reveals further positive insights

Vicore Announces Investment from Sanofi

InCarda Therapeutics Announces Results From the RESTORE-1 Phase 3 Trial and Plans for Continued Development

BONESUPPORT – SOLARIO study meets its primary endpoints – Bone substitute with local antibiotics enables reduced systemic antibiotic treatment

Vicore Publishes Prospectus Relating to the Rights Issue